

## IgE Protein, Mouse, Recombinant (His & Avi), Biotinylated

### General Information

Protein Construction: Asp198-Ser421

Species: Mouse

Expression Host: HEK293 Cells

Accession: P06336

Molecular Weight: 28.2 kDa (Predicted); 35-45 kDa (Reducing condition, due to glycosylation)

### QC Testing

Biological Activity: Immobilized Human Fc epsilon RI alpha, hFc Tag at 1 µg/ml (100 µl/well) on the plate. Dose response curve for Biotinylated Mouse IgE, His Avi Tag with the EC50 of 42.0 ng/ml determined by ELISA (QC Test).<br>Human Fc epsilon RI alpha, hFc Tag captured on CM5 Chip via Protein A can bind Biotinylated Mouse IgE, His-Avi Tag with an affinity constant of 0.42 nM as determined in SPR assay (Biacore T200).

Purity: > 95% as determined by Bis-Tris PAGE; > 95% as determined by HPLC

Endotoxin: < 1 EU/µg of the protein as determined by the LAL method.

Formulation: Lyophilized from 0.22 µm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.

### Preparation and Storage

#### Reconstitution:

Reconstitute the lyophilized protein in distilled water. The product concentration should not be less than 100 µg/ml. Before opening, centrifuge the tube to collect powder at the bottom. After adding the reconstitution buffer, avoid vortexing or pipetting for mixing.

#### Stability & Storage:

It is recommended to store recombinant proteins at -20°C to -80°C for future use. Lyophilized powders can be stably stored for over 12 months, while liquid products can be stored for 6-12 months at -80°C. For reconstituted protein solutions, the solution can be stored at -20°C to -80°C for at least 3 months. Please avoid multiple freeze-thaw cycles and store products in aliquots.

Actual storage temperature shall be subject to the COA.

#### Shipping:

In general, lyophilized powders are shipped with blue ice, while solutions are shipped with dry ice.

### Protein Background

Immunoglobulin E (IgE) is well known for its role in allergic disease, the manifestations of which are mediated through its two Fc receptors, FcεRI and CD23 (FcεRII). IgE and its interactions with these receptors are therefore potential targets for therapeutic intervention, and exciting progress has been made in this direction. Furthermore, recent structural studies of IgE-Fc, the two receptors, and of their complexes, have revealed a remarkable degree

of plasticity at the IgE-CD23 interface and an even more remarkable degree of dynamic flexibility within the IgE molecule.

**Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins**

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E\_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481